Zeyheria montana Mart. (Bignoniaceae) as source of antioxidant and immunomodulatory compounds with beneficial effects on intestinal inflammation

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 4, 2015, Pages 597-604

  Seito, Leonardo Noboru ^a   Sforcin, José Maurício ^a   Bastos, Jairo Kenupp ^b   Di Stasi, Luiz Claudio ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antioxidant activity; flavonoids; immunomodulatory activity; inflammatory bowel disease; Zeyheria montana (Bignoniaceae)

Indexed keywords

3' HYDROXY 5,7,4' TRIMETHOXYFLAVONE; 6 HYDROXY 5,7 DIMETHOXYFLAVONE; ANTIOXIDANT; FLAVONE DERIVATIVE; FLAVONOID; GLUTATHIONE; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; PLANT EXTRACT; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; ZEYHERIA MONTANA EXTRACT; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIGNONIACEAE; BIOASSAY; COLITIS; COLON INJURY; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DRUG MECHANISM; DRUG STRUCTURE; EXPERIMENTAL INFLAMMATION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; ISOLATION PROCEDURE; LIPID PEROXIDATION; MACROPHAGE; MALE; NONHUMAN; PLANT LEAF; RAT; SKIN DISEASE; TRADITIONAL MEDICINE; ULCER; ZEYHERIA MONTANA; ANIMAL; BAGG ALBINO MOUSE; BRAZIL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; INTESTINE; METABOLISM; PATHOLOGY; PHYTOTHERAPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIGNONIACEAE; BRAZIL; COLITIS; FLAVONOIDS; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINES; LIPID PEROXIDATION; MALE; MICE, INBRED BALB C; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; TRINITROBENZENESULFONIC ACID;

EID: 84925769126     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12354     Document Type: Article

References (57)

1. Katz JA, et al. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 1999; 15: 291-297.
2. Magnani M, et al. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 2000; 1: 387-399.
3. Kruidenier L, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003; 201: 17-27.
4. Ahnfelt-Ronne O, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98: 1162-1169.
5. Grisham MB,. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859-861.
6. Fina D, Pallone F,. What is the role of cytokines and chemokines in IBD? Inflamm Bowel Dis 2008; 14: S117-S118.
7. Gálvez J, et al. Effects of flavonoids on gastrointestinal disorders. In:, Atta-ur-Rahman X, ed. Studies in Natural Products Chemistry, Vol. 25. Amsterdam: Elsevier Science, 2001: 607-649.
8. Gonzáles R, et al. Dietary vitamin E supplementation protects the rat large intestine from experimental inflammation. Int J Vitam Nutr Res 2001; 71: 243-250.
9. Cuzzocrea S, et al. Tempol, a membrane permeable radical scavenger, reduces dinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol 2000; 406: 27-37.
10. Di Stasi LC, et al. Intestinal anti-inflammatory activity of paepalantine, an isocoumarin isolated from the capitula of Paepalanthus bromelioides, in the trinitrobenzenesulphonic acid model of rat colitis. Planta Med 2004; 70: 315-320.
11. Vasconcelos PCP, et al. Epicatechin used in the treatment of intestinal inflammatory disease: an analysis by experimental models. Evid Based Complement Alternat Med in press.
12. Luchini AC, et al. Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. Biol Pharm Bull 2008; 31: 1343-1350.
13. Witaicenis A, et al. Intestinal anti-inflammatory activity of esculetin and 4-methylesculetin in the trinitrobenzenesulphonic acid model of rat colitis. Chem Biol Interact 2010; 186: 211-218.
14. Witaicenis A, et al. Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. Chem Biol Interact 2012; 195: 76-85.
15. Witaicenis A, et al. Antioxidant and intestinal anti-inflammatory effects of plant-derived coumarin derivatives. Phytomedicine 2014; 21: 240-246.
16. Guenka LC, et al. Anti-inflammatory and anti-nociceptive effects of Zeyheria montana (Bignoniaceae) ethanol extract. Mem Inst Oswaldo Cruz 2008; 103: 768-772.
17. Steinert J, et al. High-performance liquid chromatographic separation of some naturally occurring naphthoquinones and anthraquinones. J Chromatogr A 1996; 723: 206-209.
18. Jácome RLRP, et al. Estudo químico de Zeyheria montana M. (bolsa-de-pastor). Rev Bras Farmacogn 2001; 11: 5-12.
19. Machado SR, et al. Ovary peltate trichomes of Zeyheria montana (Bignoniaceae): developmental ultrastructure and secretion in relation to function. Ann Bot 2006; 97: 357-369.
20. Seito LN, et al. Antiproliferative activity of three methoxylated flavonoids isolated from Zeyheria montana Mart. (Bignoniaceae) leaves. Phytother Res 2011; 25: 1447-1450.
21. Gálvez J, et al. Flavonoid inhibition of enzymic and nonenzymic lipid peroxidation in rat liver differs from its influence on the glutathione-related enzymes. Pharmacology 1995; 51: 127-133.
22. Morris GP, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
23. Bell CJ, et al. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol Gastrointest Liver Physiol 1995; 268: G622-G630.
24. Krawisz JE, et al. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984; 84: 1344-1350.
25. Bessey OA, et al. Method for rapid determination of alkaline phosphatase. J Biol Chem 1946; 164: 321-329.
26. Anderson ME,. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985; 113: 548-555.
27. Orsi RO, et al. Immunomodulatory action of propolis on macrophage activation. J Venom Anim Toxins 2000; 6: 205-219.
28. Tan EL, et al. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-(1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 2006; 6: 1-8.
29. Nordström CG, Swain T,. The flavonoid glycosides of Dahlia variabilis. Part I. General introduction. Cyanidin, apigenin, and luteolin glycosides from the variety Dandy. J Chem Soc 1953; 555: 2764-2773.
30. Osorio-Olivares M, et al. A novel route to 5,7-dimethoxy-6-hydroxyflavone. Synth Commun 1999; 29: 815-819.
31. Manthey JA, et al. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem 2001; 8: 135-153.
32. Walle T,. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin Cancer Biol 2007; 17: 354-362.
33. Shapiro H, et al. Polyphenols in the treatment of inflammatory bowel disease and pancreatitis. Gut 2007; 56: 426-436.
34. Fylaktakidou K, et al. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr Pharm Des 2004; 10: 3813-3833.
35. Comalada M, et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem Pharmacol 2006; 72: 1010-1021.
36. Sforcin JM,. Propolis and the immune system: a review. J Ethnopharmacol 2007; 113: 1-14.
37. Sánchez de Medina F, et al. Effect of quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther 1996; 278: 771-779.
38. Gálvez J, et al. Rutoside as mucosal protective in acetic acid-induced rat colitis. Planta Med 1997; 63: 409-414.
39. Cruz T, et al. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci 1998; 62: 687-695.
40. Crespo ME, et al. Antiinflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med 1999; 65: 651-653.
41. Sánchez de Medina F, et al. Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci 2002; 70: 3097-3108.
42. Kwon KH, et al. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol 2005; 69: 395-406.
43. Comalada M, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway. Eur J Immunol 2005; 35: 584-592.
44. Mochizuki M, Hasegawa N,. Therapeutic efficacy of pycnogenol in experimental inflammatory bowel diseases. Phytother Res 2004; 18: 1027-1028.
45. Ukil A, et al. Protection from experimental colitis by theaflavin-3,30-digallate correlates with inhibition of IKK and NF-kappa B activation. Br J Pharmacol 2006; 149: 121-131.
46. Kim H, et al. Metabolic and pharmacological properties of rutin, a quercetin dietary glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005; 22: 1499-1509.
47. Yamada Y, et al. A comparative analysis of two models of colitis in rats. Gastroenterology 1992; 102: 1524-1534.
48. Villegas I, et al. Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. Eur J Pharmacol 2003; 460: 209-218.
49. Veljaca M, et al. BPC-15 reduced trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 1995; 272: 417-422.
50. Cooper HS, Steplewski Z,. Immunohistologic study of ulcerative colitis with monoclonal antibodies against tumor-associated and/or differentiation antigens. Gastroenterology 1988; 95: 686-693.
51. McMahon M, et al. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45- related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001; 61: 3299-3307.
52. Neuman MG,. Immune dysfunction in inflammatory bowel disease. Transl Res 2007; 149: 173-186.
53. Atreya I, et al. NF-κB in inflammatory bowel disease. J Intern Med 2008; 263: 591-596.
54. Neurath MF, et al. Role of NF-κB in immune and inflammatory responses in the gut. Gut 1998; 43: 856-860.
55. Lõpez-Posadas R, et al. Effect of flavonoids on rat splenocytes, a structure-activity relationship study. Biochem Pharmacol 2008; 76: 495-506.
56. Tanigawa S, et al. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic Biol Med 2007; 42: 1690-1703.
57. Chae YJ, et al. Epigallocatechin-3-O-gallate inhibits the angiotensin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. Cell Physiol Biochem 2007; 20: 859-866.